RecruitMe Clinical Trial
A Randomized, open-label, Active Controlled, Safety and Extrapolated Efficacy Study in Pediatric Patients Requiring Anticoagulation for the Treatment of a Venous Thromboembolic Event
A Study of New Drug for the Treatment of Blood Clots in Children
| Sponsor: | Pfizer, Inc and Bristol-Myers Squibb BMS |
| Enrolling: | Male and Female Patients |
| Age Range: | Between 5 and 17 years old |
| IRB Number: | AAAQ7816 |
| U.S. Government ID: | NCT02464969 |
| Contact: | Cindy Neunert, MD: 212-305-9770 / cn2401@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to find out whether a new drug, called apixiban, is safe to use in children, and whether it is helpful in children with blood clots. If you choose to have your child be part of this study, s/he will either receive the experimental drug, or he/she will receive one of the usual medications that we use for children with blood clots. Neither you nor your child's doctor will choose whether your child receives the usual medications or the experimental medication.
